Therapeutic effect of statins on airway remodeling during asthma

Alabed, Mashael; Elemam, Noha Mousaad; Ramakrishnan, Rakhee K.; Sharif-Askari, Narjes Saheb; Kashour, Tarek; Hamid, Qutayba; Halwani, Rabih

doi:10.1080/17476348.2021.1987890

Cited by 7 publications

(2 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alabed M (2022) showed in his study that statins complemented the current background therapy of BA by means of providing effect on several mechanisms involved in the inflammation and remodeling processes and could be a potential therapeutic option for different BA phenotypes [36]. Our results optimized the use of statins by clarifying the possibility and feasibility of using statins in patients with BA: we demonstrated their significant effect on the remodeling marker levels and clinical efficacy (BA control, respiratory function) specifically in obese patients with late-onset BA.…”

Section: Subgroupmentioning

confidence: 99%

Effectiveness of Complex Treatment of Patients With Early-Onset and Late-Onset Bronchial Asthma Associated With Obesity

Kachkovska,

Kovchun,

Dudchenko

et al. 2024

EUMJ

View full text Add to dashboard Cite

The objective of the study was a comparative assessment of the clinical effectiveness of atorvastatin and vitamin D effect on proteolytic activity in obese patients with BA depending on the age of BA onset. Materials and Methods. We examined 195 patients with BA and obesity and 95 apparently healthy individuals. The patients were divided into 2 groups with regard to the age of BA onset: Group I included 100 patients with early-onset asthma, and Group II included 95 patients with late-onset asthma. Patients with complete BA control at baseline and those having achieved BA control after background therapy adjustment were excluded from further study. Patients of Groups I (n = 65) and II (n = 68) were divided into subgroups A, B, and C: patients of IA (n = 23) and IIA (n = 22) subgroups received background treatment in combination with vitamin D; patients of IB (n = 20) and IIB (n = 25) subgroups – in addition to background treatment received atorvastatin; patients of IC (n = 22) and IIC (n = 21) subgroups received only background treatment. To measure TIMP-1, MMP-1, and MMP-9 levels, IBL International GMBH enzyme-linked immunosorbent assay kits (Hamburg, Germany) were used. Asthma control was assessed using ACQ-5 (Asthma Control Questionnaire-5). The study was approved by the Bioethics Committee of the Academic and Research Medical Institute of Sumy State University. The obtained results were statistically processed using the SPSS–17 program. The results of the study showed that MMP-1, MMP-9, and TIMP-1 levels in obese patients with late-onset BA were significantly higher vs. patients with early-onset BA. Background therapy and its combination with vitamin D or with atorvastatin contributed to a statistically significant decrease in the level of MMP-1, MMP-9, and TIMP-1 in patients of IA, IB, and IC subgroups. MMP-1 level decreased significantly in patients with late-onset BA in all subgroups, but it was significantly lower in patients of IIB subgroup vs. IIA subgroup (p = 0.001) and IIC subgroup (p = 0.001). MMP-9 level decreased significantly in patients of IIA and IIB subgroups, but it was significantly lower in patients of IIB subgroup vs. IIA subgroup (p = 0.001) and IIC subgroup (p = 0.001). This suggested that atorvastatin contributed to a more significant decrease in MMP‑9 level vs. background therapy and background therapy + vitamin D. TIMP-1 level decreased significantly only in patients of IIB subgroup and was lower vs. IIA subgroup (p = 0.001) and IIC subgroup (p = 0.001). We demonstrated higher clinical treatment efficiency in patients of the IA subgroup who received vitamin D in addition to background therapy, which was confirmed by an increase in the level of BA control compared to that in patients of the B (p = 0.01) and C (p = 0.037) subgroups. In patients with late-onset BA (IIB subgroup), atorvastatin contributed to a better BA control compared to patients of IIA and IIC subgroups. The maximum improvement of respiratory function in patients with early-onset BA was achieved with the combination of background therapy + vitamin D, while in patients with late-onset BA – with atorvastatin. Conclusions. The use of atorvastatin has a more significant impact on the level of remodeling markers, BA control, and respiratory function in obese patients with late-onset BA vs. early-onset BA. Better BA control and maximum improvement of respiratory function in obese patients with early-onset BA were achieved with the combination of background therapy + vitamin D.

show abstract

Section: Subgroupmentioning

confidence: 99%

Effectiveness of Complex Treatment of Patients With Early-Onset and Late-Onset Bronchial Asthma Associated With Obesity

Kachkovska,

Kovchun,

Dudchenko

et al. 2024

EUMJ

View full text Add to dashboard Cite

show abstract

“…A recent study showed that triglycerides were statistically significantly higher in patients with obesity and asthma adjusted for body mass index (BMI), blood eosinophils and statin use [ 107 ]. In addition to regulation of cholesterol metabolism, the anti-inflammatory properties of statins are believed to play a role in asthma control [ 108 , 109 ]. In a recent case-control study, statin use was associated with a reduced risk of asthma-related emergency department visits, hospitalizations and systemic steroid use in patients with asthma [ 110 ].…”

Section: Metabolic Syndrome and Obesitymentioning

confidence: 99%

Hidden Comorbidities in Asthma: A Perspective for a Personalized Approach

Maule

Olivieri

Guarnieri

et al. 2023

JCM

View full text Add to dashboard Cite

Bronchial asthma is the most frequent inflammatory non-communicable condition affecting the airways worldwide. It is commonly associated with concomitant conditions, which substantially contribute to its burden, whether they involve the lung or other districts. The present review aims at providing an overview of the recent acquisitions in terms of asthma concomitant systemic conditions, besides the commonly known respiratory comorbidities. The most recent research has highlighted a number of pathobiological interactions between asthma and other organs in the view of a shared immunological background underling different diseases. A bi-univocal relationship between asthma and common conditions, including cardiovascular, metabolic or neurodegenerative diseases, as well as rare disorders such as sickle cell disease, α1-Antitrypsin deficiency and immunologic conditions with hyper-eosinophilia, should be considered and explored, in terms of diagnostic work-up and long-term assessment of asthma patients. The relevance of that acquisition is of utmost importance in the management of asthma patients and paves the way to a new approach in the light of a personalized medicine perspective, besides targeted therapies.

show abstract